For decades, kidney xenotransplantation has been presented as a possible escape from the global shortage of human organs. Now that genetically modified pig kidneys are beginning to enter formal clinical testing, a new review argues that the medical field must solve a problem that cannot be fixed by gene editing alone: how patients, families, doctors and society should decide whether the risks of an animal-to-human transplant are acceptable. The authors propose a “relational” shared decision-making framework designed specifically for kidney xenotransplantation, in which the prospective recipient’s values remain central but the potential consequences for close contacts and the wider public are also openly considered.

The review, published in Current Transplantation Reports, comes as kidney xenotransplantation enters what its authors describe as a new era. The US Food and Drug Administration has formally approved the EXPAND and EXTEND clinical trials, which will evaluate two distinct genetically engineered pig-kidney strategies in people with end-stage renal disease. EXPAND is testing a “10 GE Xenokidney,” a kidney carrying ten genetic modifications, while EXTEND is evaluating a thymokidney in which the porcine GGTA1 gene has been knocked out. The trials are intended to address safety and efficacy, but the review’s authors contend that conventional transplant consent procedures may be inadequate for a treatment whose biological, social and public-health implications extend beyond the operating room.

Xenotransplantation involves transplanting living cells, tissues or organs between different species. Pigs are considered promising donors because their organs are similar in size and physiology to human organs, and because pigs can be bred under tightly controlled conditions. Yet the biological barriers are formidable. The human immune system recognizes pig molecules as foreign, triggering antibody-mediated rejection, complement activation, cellular immune responses and inflammation. Genetic engineering aims to reduce these reactions by removing or altering pig antigens, adding human regulatory proteins and modifying pathways involved in coagulation and immune regulation. In some experimental approaches, additional changes are intended to address incompatibilities in the thymus, an organ involved in immune education. Even when these modifications improve graft survival, they do not eliminate the possibility of delayed rejection, infection, thrombosis or other complications that remain difficult to predict in humans.

The uncertainty is a defining feature of the decision. A person with end-stage renal disease may face years of dialysis, debilitating symptoms, restricted employment and travel, and a substantial risk of death while waiting for a human kidney. A pig kidney could offer earlier transplantation and potentially expand the donor supply, but the expected duration and quality of graft function remain uncertain compared with established human-to-human transplantation. Patients may also need intensive immunosuppression, which can increase susceptibility to cancer and opportunistic infections. The review emphasizes that informed consent should therefore not present xenotransplantation as simply a choice between dialysis and a functioning kidney. It should explain opportunity costs: what a patient may gain by receiving a xenokidney now, what they might lose if the graft fails, and how the decision could affect eligibility or timing for a later human transplant.

Research cited in the review suggests that willingness to accept a pig kidney is strongly shaped by concerns about inferior graft outcomes, the burden placed on relatives and the possibility of zoonotic disease transmission. These concerns are not abstract. A xenograft recipient could, in principle, harbor a pathogen adapted to pigs that is difficult to detect or treat in humans. Porcine endogenous retroviruses, porcine cytomegalovirus and atypical porcine pestivirus have been identified as issues requiring surveillance and infection-control planning, even though the actual risk differs according to the pathogen and the measures used to screen donor animals. Modern programs can use designated herds, pathogen testing, quarantine and long-term monitoring, but no screening system can guarantee that an unknown or latent infection will never cross species barriers.

That possibility creates an ethical difference between xenotransplantation and most ordinary medical choices. The person receiving the organ accepts the direct risks, but close contacts may face indirect risks if an infectious agent is transmitted. Partners, household members, caregivers and healthcare workers could be asked to participate in surveillance, modify behavior or accept restrictions designed to protect others. The public-health consequences could be broader still if a pathogen escaped detection and spread. The review draws a comparison with analytical treatment interruption studies in HIV research, where participants may face a risk of transmitting infection to sexual partners. In those studies, ethical safeguards have included partner engagement and explicit attention to third-party protection. The authors argue that xenotransplantation should similarly recognize that consent by the recipient alone may not capture everyone who could bear part of the risk.

This does not mean that family members should receive a veto over a patient’s medical care, or that recipients should be treated as vectors rather than people. Instead, the proposed relational model views autonomy as something exercised within networks of relationships, responsibilities and dependence. In traditional shared decision-making, a clinician explains the available options, the patient weighs benefits and harms, and both arrive at a choice that reflects the patient’s preferences. In a relational model, clinicians would also ask how the decision fits with the patient’s family obligations, cultural or religious commitments, caregiving arrangements and tolerance for uncertainty. With the patient’s permission, relevant partners or relatives could be included in discussions about monitoring and practical burdens, while preserving the recipient’s legal and moral authority over their own treatment.

The framework also calls for more transparent communication about uncertainty. The authors caution that optimism about a technology capable of ending the organ shortage could distort consent if experimental results are presented without their limitations. Clinicians would need to distinguish clearly between evidence from animal studies, early compassionate-use transplants and controlled clinical trials. They should explain not only what is known, but also what remains unknown: how long a modified pig kidney may function, whether immunosuppression requirements will differ from those of conventional transplantation, how infections will be monitored over decades and what options will remain if the graft fails. Evidence from other areas of medicine suggests that discussing negative features can reduce immediate acceptance while increasing trust. For a technology as visible and controversial as xenotransplantation, the review argues, trust may be more important than maximizing enrollment or short-term enthusiasm.

A practical decision aid could make these conversations more consistent. Such a tool might present dialysis, human kidney transplantation, living donation and xenotransplantation as distinct pathways rather than treating the pig kidney as an inevitable technological upgrade. It could help patients compare survival prospects, time on dialysis, quality of life, surgical risks, immunosuppression, infection precautions, possible effects on future transplantation and the demands placed on families. The authors also suggest that patient preferences should be studied systematically, including through discrete-choice experiments that measure how people trade off uncertain graft survival against shorter waiting times or fewer years on dialysis. Approaches such as a simultaneous maximum acceptable risk threshold could help investigators estimate how much combined risk patients are willing to accept for a specified potential benefit, although such numerical tools would supplement—not replace—individual conversations.

Equity is another unresolved challenge. The shortage of human kidneys already exposes patients to unequal waiting times, differing access to specialist centers and disparities linked to geography, race, income and health status. A new organ source could reduce scarcity, but it could also deepen inequities if xenotransplantation is offered primarily to people who can travel to experimental centers, pay for associated care or navigate complex consent procedures. Patients may also feel pressured to accept a risky alternative because they have been waiting too long for a human organ or cannot sustain dialysis. The review therefore places xenotransplantation within the larger ethics of allocation, insisting that a new technology should not become a shortcut around fairness. Clear eligibility rules, transparent trial recruitment and public reporting will be essential if patients are to understand why some people are offered a xenokidney while others are not.

The authors stress that the proposed framework is not a claim that kidney xenotransplantation is ready for routine care. It is a call to build ethical infrastructure before the science moves faster than public deliberation. The field has already learned from early heart xenotransplants that technical breakthroughs can rapidly capture public attention while leaving questions about long-term safety, selection and responsibility unsettled. For kidney recipients, the decision may involve not only a chance at freedom from dialysis but also lifelong infection surveillance, uncertain graft durability and obligations shared with people who never volunteered for an experiment. If clinicians communicate those realities plainly, involve families appropriately and respect the patient’s values rather than steering toward a predetermined answer, shared decision-making could help determine whether xenotransplantation earns durable public trust. The future of pig-to-human transplantation may ultimately depend as much on the quality of those conversations as on the number of genes changed in the donor animal.

Kidney transplantation is widely regarded as the optimal treatment for end-stage renal disease, significantly enhancing both survival rates and quality of life over long-term dialysis. Despite extensive research focusing on outcomes and management once patients are waitlisted or transplanted, the early stages—particularly the transition from referral to evaluation—have remained remarkably underexplored. The new study addresses this knowledge gap by meticulously analyzing data that track patient progression (or dropout) through each sequential step: referral, evaluation, waitlisting, and transplantation.

Leveraging the formidable Epic Cosmos database, which aggregates over 300 million electronic health records from more than 1,850 medical institutions—including over a third of all U.S. transplant centers—the research team was able to follow 720,348 adult patients referred for kidney transplantation between 2014 and 2025. By applying advanced statistical modeling, the researchers dissected how variables such as demographic factors, socioeconomic status, geographic location, and medical complexities influence patient trajectories through the transplant pipeline.

One of the study’s most compelling revelations is the multifaceted nature of barriers patients face long before they arrive on the transplant waitlist. Particularly vulnerable are unmarried individuals, those categorized with severe obesity, and patients residing in rural areas. These groups demonstrated disproportionately lower rates of starting and completing the transplant evaluation. The researchers suggest that limited social support, compounded by logistical challenges in accessing transplant centers mostly concentrated in urban settings, profoundly affects these disparities.

Language barriers and poverty add further layers of complexity. Older patients, Spanish speakers, and economically disadvantaged populations exhibited reduced odds of progressing beyond referral. The evaluation process itself, demanding repeated visits for comprehensive testing—including hematologic assays, radiologic imaging like chest X-rays, and oncologic screenings—can extend over months. This prolonged and intricate schedule poses significant strain on patients, particularly those simultaneously managing frequent dialysis treatments.

Institutional factors also shape patient outcomes. Smaller transplant centers, often with constrained resources and fewer transplant slots, tend to adopt more conservative patient selection criteria. This resource scarcity may lead to heightened risk aversion, amplifying the likelihood that individuals are filtered out early in the process. In contrast, larger centers with expansive infrastructure appear better suited to support patients through the complex evaluation stages, enhancing access equity.

Beyond healthcare infrastructure, psychosocial elements emerge as crucial determinants. The study highlights the importance of marital status and social support networks, which facilitate navigating the exhaustive appointment schedule and the psychological burden of chronic illness management. Candidates lacking robust social backings are more susceptible to discontinuing the transplant workup, emphasizing that transplant candidacy extends beyond physiological suitability to encompass holistic patient contexts.

The authors underscore that the transplant evaluation pathway remains one of the most intricate and strenuous journeys in medical care, entailing multifaceted specialist consultations, laboratory testing, and patient education. Each phase demands adequate patient understanding, resource availability, and logistical feasibility, accentuating the necessity for patient-centered strategies to democratize access.

Conor Donnelly, MD, the study’s lead author and PhD candidate at NYU Grossman School of Medicine, reflects on the striking influence of non-medical factors, stating the interplay of geography, healthcare center characteristics, and social environment decisively shapes transplant waitlisting outcomes. He advocates for system-level reforms targeting these upstream barriers to broaden equitable transplant access.

Allan B. Massie, PhD, co-senior author, emphasizes the potential impact of tailored educational efforts and patient navigation services to demystify and streamline the evaluation process. By reducing administrative burden and fostering comprehensible pathways, health systems can meaningfully increase the number of patients transitioning from referral to active waitlisting.

Similarly, Michal A. Mankowski, PhD, co-senior author and assistant professor of surgery, notes this study paves the way for probing analogous barriers in other organ transplant domains, each characterized by distinct logistical and clinical considerations. Expanding this research is vital for holistic transplant equity improvements.

The research, published June 20, 2026, in the Journal of the American Society of Nephrology and presented at the American Transplant Congress, marks the most extensive analysis to date of the attrition points in the kidney transplant continuum. These insights hold profound implications for policy frameworks, patient advocacy, and healthcare delivery models.

Addressing the entrenched social and systemic impediments to kidney transplantation demands coordinated efforts involving healthcare providers, payers, policymakers, and community stakeholders. Streamlining referral and evaluation protocols, augmenting support services, and ensuring resource availability at smaller centers—particularly in underserved regions—stand as imperatives.

NYU Langone Health’s funding and multidisciplinary team underscore the critical priority of tackling kidney transplant disparities with data-driven precision and commitment, aspiring to ensure that the lifesaving promise of transplantation reaches every eligible patient without undue delay or discrimination.

Subject of Research: People
Article Title: Evaluating Barriers to Kidney Transplantation in the United States
News Publication Date: 20-Jun-2026
Keywords: Organ transplantation, Renal failure, Nephropathies, Health care delivery, Health disparity, Health equity

The intricate dynamics of membrane fouling have far-reaching implications for patient outcomes. Hemodiafiltration, which combines the principles of hemodialysis and diffusion, has emerged as a promising alternative to conventional hemodialysis. However, the fouling of membranes during the filtration process remains a formidable challenge. It impacts not only the efficiency of solute removal but also the overall safety and longevity of the dialysis systems used in clinical settings.

To fully understand the fouling process, it is essential to explore the various factors contributing to this phenomenon. Membrane fouling is primarily attributed to the accumulation of proteins, lipids, and other macromolecules on the membrane surface. This accumulation leads to increased resistance and, consequently, reduced filtration efficiency. The relationship between membrane characteristics, such as pore size and surface charge, and fouling behavior has been an area of significant interest among researchers.

One of the novel findings from the study by Tange et al. indicates that the choice of dialysate composition plays a crucial role in the fouling process. By carefully selecting the ionic and osmotic properties of the dialysate, it may be possible to mitigate fouling and enhance the performance of hemodiafiltration membranes. This finding not only highlights the importance of customized therapy but also underscores the need for ongoing research into optimizing dialysate formulations.

Moreover, the study reveals that the type of therapy itself—whether hemodialysis or hemodiafiltration—can influence the degree of membrane fouling observed. Hemodialysis, characterized by its reliance on diffusion for solute removal, may lead to different fouling characteristics compared to the convective mechanisms employed in hemodiafiltration. Investigating these differences could pave the way for developing targeted strategies to minimize fouling and improve patient care.

In the clinical context, the authors emphasize the implications of fouling for treatment frequency and duration. As fouling accelerates the decline in membrane function, patients may require more frequent treatments or longer dialysis sessions. This not only affects their quality of life but also places additional burdens on healthcare systems. The insights gained from this research could lead to more personalized treatment plans that optimize the dialysis experience for patients.

Another critical aspect examined in this study is the role of membrane cleaning and maintenance protocols. Regular maintenance is essential for prolonging the lifespan of dialysis membranes and ensuring their optimal performance. The findings suggest that implementing effective cleaning strategies could significantly reduce the fouling layer’s thickness, thereby restoring membrane functionality and enhancing patient outcomes.

The interplay between membrane material properties and fouling resilience is another intriguing area explored in this research. Using cutting-edge materials science techniques, the authors delve into how different membrane compositions can inherently resist fouling. By engineering membranes with specific surface characteristics, it may be possible to develop next-generation dialysis filters that maintain high efficiency over extended periods.

The insights offered by Tange and colleagues could potentially lead to a paradigm shift in how dialysis treatment is approached. Given the increasing prevalence of chronic kidney disease worldwide, improving the performance of hemodialysis and hemodiafiltration membranes has never been more critical. The implications of their research extend beyond individual therapies, hinting at broader applications in the biomedical field, such as enhancing filtration processes in other organ support systems.

In conclusion, the research conducted by Tange, Kawakami, and Takesawa not only addresses a pivotal challenge in dialysis therapy but also opens up avenues for future investigation. As the field of artificial organs continues to evolve, the findings reported in this study underscore the necessity of interdisciplinary collaboration among biochemists, materials scientists, and clinical practitioners to fully harness the potential of hemodiafiltration therapies.

In summary, ongoing research into membrane fouling highlights the importance of understanding the intricate mechanics of dialysis therapies. The work of Tange and his team emphasizes the need for targeted strategies to combat fouling, optimize treatment protocols, and ultimately improve the quality of life for patients undergoing renal replacement therapies. The scientific community eagerly anticipates further developments in this vital area, which has the potential to transform patient care in the arena of end-stage renal disease.

As researchers continue to explore the multifactorial nature of membrane fouling, the importance of incorporating patient-specific parameters will become increasingly evident. The ultimate goal is to create tailored dialysis experiences that not only extend the life of artificial organs but also enhance the overall health outcomes for patients. The findings from this study are a crucial step in that direction.

By addressing the fouling process comprehensively, Tange, Kawakami, and Takesawa contribute significantly to the growing body of literature aiming to enhance the efficiency and effectiveness of hemodialysis and hemodiafiltration. This work not only broadens our understanding of membrane behavior but also stresses the critical need for innovation in therapeutic strategies for renal replacement therapies.

Subject of Research: Membrane fouling in hemodialysis and hemodiafiltration therapy.

Article Title: Fouling process of hemodiafiltration membranes by hemodialysis and hemodiafiltration therapy.

Article References:

Tange, Y., Kawakami, M. & Takesawa, S. Fouling process of hemodiafiltration membranes by hemodialysis and hemodiafiltration therapy.
J Artif Organs 28, 408–414 (2025). https://doi.org/10.1007/s10047-025-01497-9

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10047-025-01497-9

Keywords: Membrane fouling, hemodialysis, hemodiafiltration, dialysis therapy, renal replacement therapy.